Active Clinical Trials

Phase II Trial of Alisertib (MLN8237) in Salvage Malignant Mesothelioma

By April 24, 2017 No Comments

Condition

Lung Cancer|Mesothelioma

Estimated Enrollment: 28

Age Group: 18 Years and older   (Adult, Senior)

Gender: All

Study Type: Interventional

Study Design Allocation: Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment

Study ID Numbers: 2014-0497|NCI-2014-02568

Study First Received: November 11, 2014

Last Updated: February 15, 2017

Estimated Primary Completion Date: May 2021

 

Primary Outcome Measures:

Disease Control Rate (DCR)|Response Rate

Sponsors and Collaborators:

M.D. Anderson Cancer Center|Millennium Pharmaceuticals, Inc.

Website Link: https://ClinicalTrials.gov/show/NCT02293005

Leave a Reply

Call Now ButtonCall Now